Head-and-neck-primelines

Overall Survival Benefit for Pembrolizumab in Head and Neck Cancer

In recent years, the standard of care in recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has shifted dramatically. Historically, the chemotherapy and cetuximab containing EXTREME regimen has been the preferred first-line treatment in this setting, though this regimen is associated with high rates of toxicity and can be difficult for patients to […]

Read More

ovarian-cancer-primelines

Is Surgery Appropriate for Patients With Recurrent Ovarian Cancer?

When patients with ovarian cancer develop recurrent disease, secondary surgical cytoreduction followed by platinum-based chemotherapy is a common treatment approach. However, the efficacy of this approach previously has not been verified in a prospective phase III trial. In an attempt to answer that question, the GOG-0213 trial compared secondary cytoreduction followed by chemotherapy to chemotherapy […]

Read More

PSA Screening for Prostate Cancer Among Men With BRCA2 Mutations

Mutations in BRCA1 and BRCA2 genes are highly associated with increased risk of breast and ovarian cancer among women. In men, presence of between BRCA2 mutations has been shown to be associated with an increased risk of prostate cancer and overall poor prognosis. Early detection is key in successful treatment of prostate cancer, and prostate […]

Read More

Predicting Six-Month Mortality Among Patients With Cancer

When physicians have conversations with their patients regarding advanced care early during treatment, it results in patients receiving care that is in line with their goals and wishes. While guidelines recommend conversations with high-risk patients regarding advanced care, many patients with cancer die without ever having had this conversation. Because oncologists are only able to […]

Read More